Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.

In the overall population, weight change from baseline to the last day of the highest well-tolerated dose did not reach statistical significance [LS mean (s.e.) difference −0.59 (0.43) and −0.49 (0.42) kg versus placebo for the lixisenatide QD- and BID-treated patients, respectively].

also in 75,278 other papers

Overall, and for both ethnicities, there was a numerical trend towards a greater treatment effect with lixisenatide QD compared with lixisenatide BID.

also in 723 other papers